Hospital
Baptist Hospital of Miami INC
Baptist Hospital of Miami INC was paid $31.88M by Medicaid between Jan 2018 and Dec 2024, across 366 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoBAPTIST HOSPITAL OF MIAMI INC
MIAMI, FL 33176
MIAMI, FL 33176
33aNPI1528042884assigned 11/30/2005
33bProvider typeRehabilitation Hospital Unit
28Total paid$31.88M
24GClaims1,415,289
24DCodes billed366
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in Florida
Rank by total paid#1 of 11
Median peer was paid$15.92M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 148,744 | $1.98M | |
| 2019 | 307,066 | $7.00M | |
| 2020 | 216,043 | $4.76M | |
| 2021 | 278,668 | $5.88M | |
| 2022 | 296,262 | $7.33M | |
| 2023 | 128,763 | $3.60M | |
| 2024incomplete | 39,743 | $1.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 45,264 | 40,031 | $4.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.3% | 31,041 | 27,787 | $2.96M |
| 36415 | Collection of venous blood by venipuncture | 5.9% | 47,565 | 31,449 | $1.88M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.5% | 14,708 | 6,666 | $1.13M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.5% | 1,010 | 648 | $1.11M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 18,101 | 15,365 | $1.04M |
| 77336 | 2.7% | 3,399 | 1,249 | $875K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 6,119 | 5,333 | $869K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 7,631 | 6,516 | $835K |
| 77387 | 2.6% | 2,159 | 172 | $830K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.5% | 46,124 | 40,700 | $784K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 43,269 | 38,645 | $752K |
354 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 88,676 | $737K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.1% | 12,109 | $659K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 4,778 | $619K |
| J9035 | Injection, bevacizumab, 10 mg | 1.3% | 1,837 | $419K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.3% | 30,789 | $414K |
| G0378 | Hospital observation service, per hour | 1.2% | 15,574 | $386K |
| 77300 | 1.1% | 1,428 | $344K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 35,230 | $333K |
| 77523 | 1.0% | 984 | $330K | |
| 96415 | 1.0% | 3,332 | $323K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 44,945 | $309K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 2,930 | $299K |
| 80053 | Comprehensive metabolic panel | <1% | 21,545 | $273K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 6,241 | $255K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,518 | $230K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,507 | $226K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,995 | $220K |
| 82962 | <1% | 8,259 | $207K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 24,057 | $190K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 777 | $187K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,002 | $179K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,470 | $177K |
| 96417 | <1% | 4,025 | $166K | |
| 87081 | <1% | 27,522 | $163K | |
| 80076 | <1% | 20,010 | $151K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,315 | $151K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,430 | $149K |
| 96416 | <1% | 1,753 | $146K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 8,815 | $146K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 14,336 | $143K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 11,457 | $142K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,865 | $142K |
| 96402 | <1% | 3,104 | $139K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,660 | $131K |
| 87428 | <1% | 9,455 | $126K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 313 | $121K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 1,467 | $112K |
| 77334 | <1% | 1,389 | $111K | |
| 81003 | <1% | 14,395 | $109K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,150 | $106K |
| 86850 | <1% | 5,933 | $105K | |
| 86901 | <1% | 6,011 | $94K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,864 | $94K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,100 | $86K |
| 87088 | <1% | 13,522 | $85K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,895 | $84K |
| 73630 | <1% | 3,664 | $81K | |
| 86900 | <1% | 6,299 | $81K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,211 | $78K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,789 | $75K |
| 96411 | <1% | 1,527 | $75K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 1,033 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,785 | $73K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 600 | $73K |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 1,324 | $71K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,924 | $66K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,378 | $65K |
| 96367 | <1% | 8,324 | $63K | |
| 87430 | <1% | 27,923 | $60K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,939 | $59K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,688 | $58K |
| 77412 | <1% | 768 | $57K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,947 | $56K |
| 82947 | <1% | 10,690 | $55K | |
| 73610 | <1% | 2,901 | $55K | |
| 97161 | <1% | 2,353 | $55K | |
| A9270 | Non-covered item or service | <1% | 13,924 | $53K |
| 72131 | <1% | 895 | $53K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,467 | $52K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,703 | $51K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,882 | $51K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 2,421 | $50K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 1,208 | $49K |
| 86738 | <1% | 2,645 | $48K | |
| 73130 | <1% | 2,423 | $48K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 35,566 | $47K |
| 73562 | <1% | 3,088 | $46K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 987 | $45K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,844 | $45K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,399 | $42K |
| 77295 | <1% | 175 | $42K | |
| 87581 | <1% | 4,028 | $41K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,154 | $41K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,017 | $40K |
| 77301 | <1% | 185 | $39K | |
| 87486 | <1% | 5,379 | $36K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,148 | $35K |
| 96401 | <1% | 1,104 | $35K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,375 | $34K |
| 75574 | <1% | 425 | $33K | |
| 36430 | <1% | 1,307 | $33K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,302 | $32K |
| 88341 | <1% | 954 | $32K | |
| C1769 | Guide wire | <1% | 891 | $32K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,114 | $32K |
| 73110 | <1% | 1,866 | $30K | |
| 71250 | <1% | 1,223 | $29K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,083 | $27K |
| 96523 | <1% | 3,098 | $27K | |
| 81025 | <1% | 8,990 | $27K | |
| 87507 | <1% | 652 | $27K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,899 | $27K |
| 10060 | <1% | 370 | $27K | |
| 44970 | <1% | 55 | $27K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,200 | $27K |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | <1% | 609 | $25K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,203 | $25K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,671 | $25K |
| 93970 | <1% | 1,550 | $24K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 732 | $24K |
| 74018 | <1% | 1,932 | $24K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,784 | $24K |
| 81001 | <1% | 18,627 | $24K | |
| 84112 | <1% | 159 | $23K | |
| 76801 | <1% | 1,576 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,414 | $22K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,251 | $22K |
| 87807 | <1% | 2,987 | $21K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,743 | $21K |
| 73030 | <1% | 1,957 | $21K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,485 | $21K |
| 87186 | <1% | 4,788 | $20K | |
| 84132 | <1% | 5,644 | $20K | |
| 77386 | <1% | 214 | $20K | |
| 87040 | <1% | 3,275 | $20K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,654 | $20K |
| 73080 | <1% | 976 | $19K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,746 | $19K |
| 80047 | <1% | 1,594 | $18K | |
| 72100 | <1% | 1,561 | $18K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 543 | $18K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 605 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,416 | $18K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,040 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,318 | $18K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 677 | $17K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,154 | $17K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,182 | $17K |
| 77338 | <1% | 48 | $17K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,050 | $16K |
| 88185 | <1% | 684 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,719 | $15K |
| 88342 | <1% | 1,365 | $14K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,954 | $14K |
| 80051 | <1% | 2,834 | $14K | |
| 73140 | <1% | 721 | $14K | |
| 87077 | <1% | 5,513 | $14K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 113 | $13K |
| 82565 | <1% | 7,987 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,585 | $13K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 450 | $13K |
| 96409 | <1% | 172 | $13K | |
| 85027 | <1% | 5,365 | $13K | |
| 76775 | <1% | 468 | $13K | |
| 84520 | <1% | 7,848 | $12K | |
| 83735 | <1% | 8,086 | $12K | |
| 85610 | <1% | 12,699 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 691 | $12K |
| 86923 | <1% | 1,090 | $11K | |
| 72040 | <1% | 528 | $11K | |
| 96376 | <1% | 4,462 | $11K | |
| 82378 | <1% | 4,296 | $11K | |
| 96368 | <1% | 1,561 | $10K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 82 | $10K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,240 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,525 | $10K |
| 85730 | <1% | 11,298 | $10K | |
| 87116 | <1% | 175 | $10K | |
| 73502 | <1% | 941 | $10K | |
| 82150 | <1% | 2,167 | $10K | |
| 83615 | <1% | 5,687 | $10K | |
| 84295 | <1% | 5,028 | $10K | |
| 12011 | <1% | 403 | $9K | |
| 84100 | <1% | 2,831 | $9K | |
| 76770 | <1% | 289 | $9K | |
| 86308 | <1% | 1,321 | $9K | |
| 71101 | <1% | 518 | $9K | |
| 77290 | <1% | 76 | $8K | |
| 82374 | <1% | 4,920 | $8K | |
| 82435 | <1% | 4,996 | $8K | |
| 85379 | <1% | 3,114 | $8K | |
| 84145 | <1% | 1,605 | $7K | |
| 99205 | Prolong outpt/office vis | <1% | 241 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 258 | $7K |
| 74021 | <1% | 637 | $7K | |
| 73590 | <1% | 511 | $7K | |
| 84484 | <1% | 11,677 | $7K | |
| 84703 | <1% | 9,262 | $6K | |
| 80061 | Lipid panel | <1% | 2,605 | $6K |
| 96377 | <1% | 307 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,583 | $6K |
| 83880 | <1% | 2,261 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,767 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 111 | $6K |
| 86300 | <1% | 1,972 | $6K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 244 | $5K |
| 70491 | <1% | 43 | $5K | |
| 83690 | <1% | 9,018 | $5K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 279 | $5K |
| 87205 | <1% | 1,583 | $5K | |
| 12001 | <1% | 344 | $5K | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 123 | $5K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 218 | $4K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,951 | $4K |
| 73090 | <1% | 304 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,258 | $4K |
| 97162 | <1% | 58 | $4K | |
| 88304 | <1% | 593 | $4K | |
| 87070 | <1% | 917 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,058 | $4K |
| 80069 | <1% | 130 | $4K | |
| 83883 | <1% | 994 | $3K | |
| 64483 | <1% | 82 | $3K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 456 | $3K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 33 | $3K |
| 82784 | <1% | 1,328 | $3K | |
| 70486 | <1% | 45 | $3K | |
| 84550 | <1% | 2,263 | $3K | |
| 87210 | <1% | 902 | $3K | |
| 82310 | <1% | 631 | $3K | |
| 82728 | <1% | 2,759 | $3K | |
| 29125 | <1% | 348 | $3K | |
| 29515 | <1% | 119 | $3K | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 103 | $3K |
| J3490 | Unclassified drugs | <1% | 1,312 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,121 | $2K |
| 83550 | <1% | 2,207 | $2K | |
| 83540 | <1% | 2,283 | $2K | |
| 90715 | <1% | 1,402 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $2K |
| 36416 | <1% | 602 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,617 | $2K |
| 82272 | <1% | 56 | $2K | |
| 82805 | <1% | 357 | $2K | |
| 83605 | <1% | 5,555 | $2K | |
| 87209 | <1% | 45 | $2K | |
| 93976 | <1% | 182 | $2K | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 184 | $2K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 21 | $2K |
| 82731 | <1% | 13 | $2K | |
| 87046 | <1% | 644 | $2K | |
| 86140 | <1% | 6,614 | $2K | |
| 82607 | <1% | 1,835 | $2K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 132 | $2K |
| 82570 | <1% | 118 | $2K | |
| 84153 | <1% | 533 | $2K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 77 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,455 | $2K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 213 | $2K |
| 87899 | <1% | 545 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 186 | $1K |
| 82232 | <1% | 728 | $1K | |
| 88184 | <1% | 474 | $1K | |
| 87045 | <1% | 345 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 916 | $1K |
| 84702 | <1% | 1,944 | $1K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 269 | $1K |
| 88307 | <1% | 13 | $1K | |
| 82040 | <1% | 736 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,436 | $1K |
| 76870 | <1% | 20 | $993.08 | |
| 85097 | <1% | 33 | $991.28 | |
| 19083 | <1% | 22 | $893.57 | |
| 82247 | <1% | 682 | $858.91 | |
| 99152 | <1% | 16 | $850.64 | |
| 76942 | <1% | 43 | $841.57 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,197 | $769.98 |
| 89051 | <1% | 115 | $758.63 | |
| 85652 | <1% | 1,758 | $713.23 | |
| 77280 | <1% | 42 | $705.58 | |
| 84075 | <1% | 231 | $678.27 | |
| 87147 | <1% | 399 | $677.30 | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 821 | $672.86 |
| 84155 | <1% | 185 | $638.51 | |
| 82746 | <1% | 1,260 | $622.95 | |
| 95819 | <1% | 50 | $578.94 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 845 | $562.72 |
| 69210 | <1% | 176 | $527.11 | |
| 86663 | <1% | 75 | $489.16 | |
| 84450 | <1% | 407 | $459.30 | |
| 84460 | <1% | 405 | $444.09 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 895 | $414.21 |
| 77001 | <1% | 13 | $404.40 | |
| 31575 | <1% | 16 | $399.50 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 625 | $385.62 |
| 87015 | <1% | 74 | $357.94 | |
| 87206 | <1% | 73 | $357.94 | |
| 87102 | <1% | 98 | $357.94 | |
| 97165 | <1% | 451 | $322.51 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 347 | $314.02 |
| 85045 | <1% | 801 | $296.58 | |
| 82550 | <1% | 1,083 | $296.23 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 116 | $287.78 |
| 82977 | <1% | 205 | $270.53 | |
| 88108 | <1% | 31 | $263.84 | |
| 77370 | <1% | 16 | $261.24 | |
| 88360 | <1% | 59 | $252.99 | |
| 93923 | <1% | 16 | $250.15 | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 35 | $238.87 |
| 93880 | <1% | 47 | $224.71 | |
| 36591 | <1% | 20 | $222.89 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 67 | $195.42 |
| 83521 | <1% | 661 | $189.00 | |
| 83045 | <1% | 294 | $182.64 | |
| 86301 | <1% | 273 | $177.81 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 73 | $173.34 |
| 86665 | <1% | 147 | $164.83 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 196 | $162.95 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 235 | $157.66 |
| 82376 | <1% | 315 | $157.25 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 47 | $154.04 |
| 73552 | <1% | 18 | $148.06 | |
| 86664 | <1% | 75 | $126.62 | |
| 84439 | <1% | 509 | $123.34 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 396 | $115.30 |
| 87075 | <1% | 163 | $102.64 | |
| 88312 | <1% | 38 | $101.92 | |
| 84403 | <1% | 76 | $100.17 | |
| 86592 | <1% | 196 | $89.48 | |
| 82248 | <1% | 173 | $85.26 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 67 | $77.50 |
| 76937 | <1% | 19 | $70.49 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 266 | $53.05 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $52.30 |
| 80074 | <1% | 22 | $47.23 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 127 | $40.12 |
| 72072 | <1% | 14 | $35.85 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 153 | $26.73 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 59 | $26.62 |
| 86769 | <1% | 28 | $21.29 | |
| 86304 | <1% | 63 | $18.98 | |
| 88300 | <1% | 49 | $15.34 | |
| 87493 | <1% | 17 | $6.06 | |
| 87425 | <1% | 28 | $6.05 | |
| 87181 | <1% | 19 | $5.48 | |
| J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | <1% | 83 | $0.30 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 561 | $0.00 |
| 82945 | 0% | 52 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 32 | $0.00 |
| 82077 | 0% | 30 | $0.00 | |
| 88311 | 0% | 68 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 108 | $0.00 |
| 84157 | 0% | 54 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 20 | $0.00 |
| 99199 | Unlisted special service, procedure or report | 0% | 315 | $0.00 |
| 00840 | 0% | 35 | $0.00 | |
| 88313 | 0% | 13 | $0.00 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 199 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 44 | $0.00 |
| 49083 | 0% | 19 | $0.00 | |
| 38222 | 0% | 35 | $0.00 | |
| 85384 | 0% | 55 | $0.00 | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 35 | $0.00 |
| 94664 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialULBRICHT, WILLIAM (CEO)